At a glance:
- All three US major indices had a volatile month in February, closing lower after hitting record highs.
- Amid concerns about rising bond yields which may hurt high-growth tech stocks the most, the Nasdaq Composite underperformed, with an 8% correction from its 14,000 high.
- Investors rotated from high-growth tech stocks to cyclical sectors which are sensitive to economic re-opening.
Here are February’s top 10 traded US stocks on Phillip’s Online Electronic Mart System (POEMS), based on gross market value traded.
All three US major indices – Dow Jones, S&P 500 and Nasdaq Composite – scaled new heights in mid-to-late February, before closing sharply lower at the end of the month. The Dow and S&P 500 broke new records of 32,000 and 3,900 points respectively, before retracing lower. They still closed higher than January levels of slightly below 31,000 and 3,800 points. The Nasdaq Composite hit a record 14,100 points in mid-February but corrected more than 8% to close slightly lower than its January close of 13,000 points.
With the Reddit trading frenzy slowly subsiding and trading activities returning to normal, investors shifted their focus back to earnings. Rising bond yields spooked many as they questioned the Fed’s commitment to low rates amid the economic recovery. This prompted a flight from high-growth stocks as valuations came into question in the middle of uncertainties over easy monetary policies.
We have included technical charts for all of the top 10 counters. These are based on 4-hourly time frames over 30/40 days. The charts are for your information only and support and resistance levels discussed are solely based on our dealers’ views. The technical charts should not be constituted as buy or sell recommendations and investors/traders are advised to do their own due diligence before making any trade.
Starting from the 10th position:
10th: Moderna Inc (NASDAQ: MRNA)
After dropping out of the top 10 list in January, Moderna clawed back its 10th spot in February. The COVID-19 vaccine maker struck an all-time high of US$187.50 on 9 February before losing more than 23% to end the month at a low of US$143.62 on 23 February.
With Moderna’s vaccine shot appearing more effective than rivals – which recently reported data against new strains of COVID-191, the vaccine maker hopes to produce more than 700 million doses in 2021, with the potential for as many as 1 billion doses2. The company is also expecting US$18.4bn in vaccine sales this year, putting it on track for its first profit since its founding in 20103.
Rival AstraZeneca has just cashed out of its stake in Moderna, raking in US$1bn. This came after Moderna’s meteoric rise in the past year4. With this disclosure, investors might have been spooked into taking profit, as Moderna went public at US$23 a share vs its February close of US$154.81 – which represented more than a 600% increase!
Technical Analysis:
Status: Technical Sell
Support: around US$121.12 (recent low)
Resistance: around US$140 (20-period moving average)
Moving average cross-down indicates a likely downtrend.
9th: Riot Blockchain Inc (NASDAQ: RIOT)
A newcomer to our list, Riot is a digital-currency company that invests in cryptocurrency and block chain entities. Its share price closely mimics the extreme volatility of many cryptocurrencies.
From a February opening price of US$18.81, it catapulted to US$77.90 on 18 February, more than a 400% increment. This paralleled the movements of the largest cryptocurrency, bitcoin, which smashed a record of US$58,000 around the same time. However, the cryptocurrency company’s share price subsequently plummeted by more than 40% to close at US$43.74 at end-February.
Investments in such companies are slowly gaining popularity as investors look to gain exposure to cryptocurrencies. This explains the recent surges in Riot’s share price and trading volumes. Further volatility can be expected, as cryptocurrencies remain highly speculative.
Technical Analysis:
Status: Neutral
Support: US$35-40 (recent low)
Resistance: around US$48 (20- and 50-period moving averages)
Moving averages appear to be sloping downwards. 20-period MA looking to cross below 50-period MA. May indicate a downtrend.
8th: Alibaba Group Holding Ltd – ADR (NYSE: BABA)
Dropping two ranks, Alibaba came in 8th in February. Share price rallied around 8% initially to this year’s high of US$273.85 before selling pressure kicked in, causing it to correct by 13%. It closed at US$237.73 in February.
The company started the month in good standing with its US$5mn bond sale attracting more than US$38bn orders5. This demonstrated investors’ confidence in the e-commerce giant as they shrugged off antitrust fears and look to the future of China’s e-commerce and cloud industries.
However, nearing the end of the month, the Bill and Melinda Gates Foundation disclosed its entire exit from Alibaba at a US$232.73 price for a total of US$128.56mn6. This re-introduced selling pressure even as the Chinese giant continues to be plagued by regulatory and antitrust threats.
Technical Analysis:
Status: Technical Sell
Support: US$228.34 (recent low)
Resistance: US$238-240 (20-period moving average)
Moving average cross-down indicates a likely downtrend.
7th: Sundial Growers (NASDAQ: SNDL)
Sundial Growers, another newcomer to our top 10 and one of the stocks recently embroiled in the Reddit mania, is a target of retail investors’ extreme speculation. Share price vaulted more than 300% from its January close of US$0.815 to a month-high of US$3.35 on 11 February. It then crashed 160% to a February close of US$1.33 right after.
Besides speculation, certain fundamentals might have improved the company’s reputation. There is growing optimism that the US Congress may lift some restrictions on cannabis. This is positive for the company’s cannabis-related business. Sundial grows a range of cannabis strains and sells a variety of cannabis-derivative products. The company also recently closed out stock and cash investments in edible producer, Indiva, another licensed Canadian cannabis producer. It is set to put this capital to work on growth7.
While cannabis investing is picking up, extreme volatility makes this stock unsuitable for risk-averse investors.
Technical Analysis:
Status: Technical Sell
Support: US$1 (recent low)
Resistance: US$1.30 (20-period moving average)
Moving average cross-down indicates a likely downtrend.
6th: Apple Inc (NASDAQ: AAPL)
A staple in our top 10, Apple slipped from No. 3 in January to No. 6 in February. Despite a stellar set of quarterly results, the tech giant underperformed the broader market as investors rotate from high growth tech companies to value / cyclical companies. Its share price retraced from a month-high of US$137.39 on 4 February to US$121.26, down more than 11%.
The recent correction may offer an opportunity to buy into one of the largest companies with record earnings to boot. What’s more, Apple is diversifying away from the iPhone to augmented reality. AR has the potential to become the next big thing in tech.
Technical Analysis:
Status: Technical Sell
Support: around US$118 (recent low)
Resistance: around US$125 (downtrend line)
Downtrend line formed.
5th: Square Inc (NYSE: SQ)
Square retained its fifth spot in February. It further skyrocketed to a new record of US$281.09 on 16 February, before succumbing to the broader market selloff towards the end of the month. It closed 18% off its high at US$230.
Even though Square announced a stronger-than-expected quarterly EPS of US$0.32 vs the Street’s US$0.24, its shares slumped after it announced a new purchase of bitcoins. The company had snapped up another 3,318 bitcoins for US$170mn. The cryptocurrency now represents about 5% of Square’s 2020 cash holdings8.
Investors didn’t seem to stomach Square’s appetite for cryptocurrencies well, even though Square sees a need for the Internet to have a native currency9.
Technical Analysis:
Status: Neutral
Support: around US$200 (recent low)
Resistance: around US$230 (20-period moving average)
US$200 supporting well at the moment. 20 MA cross-down below 50 MA may indicate a downtrend. Take note of support level at US$200. A breakdown and close below this level could indicate further downside.
4th: Palantir Technologies Inc (NYSE: PLTR)
Palantir retained its 4th spot in the month. After breaking a record at the end of January, Palantir retreated a little before testing a month-high of US$38.39 in February. It then gave up 38% to close the month at US$23.90.
Recent weakness may be attributed to its earnings shortfall. EPS came in at -US$0.08 vs the Street’s estimate of US$0.0210.
The data analytics company is projecting more than 30% YoY growth for 202111. This underscores its optimism on the usability of its software for enabling data integration and modularity. However, the company is a government IT provider, with revenue from the government accounting for more than 60% of its total. This means Palantir heavily relies on its government business for its success. The company may need to diversify its revenue stream further to prevent the adverse scenario of termination of government contracts which will heavily affect the company’s business.
Technical Analysis:
Status: Neutral
Support: around US$22 (recent low)
Resistance: around US$25 (20-period moving average)
US$22 supporting well at the moment. 20 MA cross-down below 50 MA may indicate a downtrend. Take note of support level at US$22. A breakdown and close below this level could indicate further downside.
3rd: Futu Holdings Ltd (NASDAQ: FUTU)
Yet another newcomer to our top 10 list is Futu Holdings, one of the most disruptive companies in the brokerage and wealth-management circle. Known as the Robinhood of China, it muscled its way to the top 3 in February. Like its US counterpart, Futu’s introduction of no commission trading and fractional share ownership helped to create an explosion in retail trading and speculation in call options in China.
Futu’s share price has been on a tear since the start of the year, rising close to 300% to a high of US$191 on 16 February. After that, it corrected by about 20% to close at US$152.79 towards month-end.
The explosion in its share price may be attributed to a few factors. One is the mushrooming of retail trading that is happening across the globe, particularly benefitting the stockbroking and trading industry. Two, unlike many early-stage tech start-ups, Futu is already a profitable company on the back of the recent eruption in retail trading. However, as with many high-growth companies, caution is warranted, as volatility in such companies is likely to persist due to increased speculation.
Technical Analysis:
Status: Technical Sell
Support: US$95-100 (recent low/psychological level)
Resistance: around US$150 (20-period moving average)
20 MA cross-down below 50 MA may indicate a downtrend.
2nd: Nio Inc (NYSE: NIO)
A staple in our list, this Chinese EV maker defended its second position for the third straight month. Nio soared to another record high of US$62.84 on 10 February. However, it crashed right after to close at US$45.78, more than a 28% drop.
Its initial rise could be credited to record monthly deliveries of 7,225 vehicles, up 352% YoY12. Unfortunately, despite its record deliveries, earnings missed analysts’ estimates. Nio’s loss came in at RMB1.49bn vs expectations of RMB757mn. This renewed questions about the profitability of the EV industry, especially with so many companies vying for a share of the pie. On a brighter note, Nio’s revenue has crossed the billion-dollar mark for the first time. In order to be profitable, the company would need to control costs and improve margins.
Technical Analysis:
Status: Technical Sell
Support: US$32 (recent low)
Resistance: around US$42.50 (20-period moving average)
20 MA cross-down below 50 MA may indicate a downtrend. Take note of oversold conditions on RSI.
1st: Tesla Motors Inc (NASDAQ: TSLA)
Ruling the list yet again is the king of EVs, Tesla. Though its share price was on a downtrend for the entire month of February, it still had secured the top spot for three consecutive months. Share price dropped from a near-record high of US$873 at the beginning of the month to close at US$675 towards month-end, down 30%. Its performance turned negative for the first time after a historic run since its inclusion in the S&P 500. It briefly went below the price it was trading at when it was inducted into the S&P 500, after its biggest intraday drop of more than 12% to US$627 on 23 February. This came after a decline of 8.6% the previous day.
Tesla’s recent weakness may have been caused by its recent US$1.5bn investment in Bitcoin. This was followed by comments from CEO Elon Musk that cryptocurrency prices did seem high13. The sharp decline in Tesla tracked the tumble seen in the price of Bitcoin around the same period.
Though selling pressure was strong, popular fund manager, Cathie Wood, snapped up more shares of the EV maker during its 12% dip. She bought 240,548 shares and mentioned in passing that the shakeout was a healthy one common in all bull markets14. That aside, Tesla’s share price may be in for further wild swings as investors closely watch its investments in Bitcoin.
Technical Analysis:
Status: Technical Sell
Support: around US$540 (recent low)
Resistance: around US$650 (20-period moving average)
20 MA cross-down below 50 MA may indicate a downtrend. Take note of oversold conditions on RSI.
Check out our full series on ‘Top 10 Traded US Stocks on POEMS’ here!
Have a view on the above? Join our global investment community on Telegram and share your thoughts and views with us today!.
References:
1. https://www.forbes.com/sites/greatspeculations/2021/02/10/why-has-moderna-stock-already-rallied-75-in-2021/?sh=6416772449f2
2. https://www.channelnewsasia.com/news/business/moderna-sees-us-18-4-billion-in-sales-from-covid-19-vaccine-in-2021-14281456
3. https://www.channelnewsasia.com/news/business/astrazeneca-sells-stake-in-vaccine-maker-moderna-for-nearly-us-1-billion-14304732
4. https://www.channelnewsasia.com/news/business/astrazeneca-sells-stake-in-vaccine-maker-moderna-for-nearly-us-1-billion-14304732
5. https://www.straitstimes.com/business/companies-markets/investors-flock-to-us5b-alibaba-bond-deal-shrug-off-regulatory-woes
7. https://www.fool.com/investing/2021/02/25/why-sundial-growers-stock-jumped-then-dropped-toda/
8. https://www.thestreet.com/investing/square-drops-despite-quarterly-beats-buys-more-bitcoin
9. https://www.cnbc.com/2021/02/23/square-buys-170-million-worth-of-bitcoin.html
10. https://www.fxstreet.com/news/breaking-palantir-results-miss-earnings-per-share-loss-but-revenue-beats-202102161210
11. https://investors.palantir.com/news-details/2021/Palantir-Reports-Revenue-Growth-of-47-for-Full-Year-2020-Expects-Q1-2021-Revenue-Growth-of-45
12. https://www.nasdaq.com/articles/is-nio-stock-a-buy-after-its-january-delivery-numbers-2021-02-01
13. https://www.businesstimes.com.sg/transport/tesla-sinks-below-the-price-at-which-it-entered-sp-500
14. https://fortune.com/2021/02/24/cathie-woods-arkk-tesla-tech/
Disclaimer
We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock`s risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation
GENERAL DISCLAIMER
This publication is prepared by Phillip Securities (Hong Kong) Ltd (“Phillip Securities”). By receiving or reading this publication, you agree to be bound by the terms and limitations set out below.
This publication shall not be reproduced in whole or in part, distributed or published by you for any purpose. Phillip Securities shall not be liable for any direct or consequential loss arising from any use of material contained in this publication.
The information contained in this publication has been obtained from public sources which Phillip Securities has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in this publication are based on such information and are expressions of belief only. Phillip Securities has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will Phillip Securities be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time without prior notice.
This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a financial adviser regarding the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This publication should not be relied upon as authoritative without further being subject to the recipient`s own independent verification and exercise of judgment. The fact that this publication has been made available constitutes neither a recommendation to enter into a particular transaction nor a representation that any product described in this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products which may be described in this publication involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in this research should take into account existing public information, including any registered prospectus in respect of such security.
Disclosure of Interest
Analyst Disclosure: Neither the analyst(s) preparing this report nor his associate has any financial interest in or serves as an officer of the listed corporation covered in this report.
Firm`s Disclosure: Phillip Securities does not have any investment banking relationship with the listed corporation covered in this report nor any financial interest of 1% or more of the market capitalization in the listed corporation. In addition, no executive staff of Phillip Securities serves as an officer of the listed corporation.
If Distribution is to Australian Investors
This report is produced by Phillip Securities (Hong Kong) Ltd and is being distributed in Australia by Phillip Capital Limited (Australian Financial Services License No. 246827). This report contains general securities advice and does not take into account your personal objectives, situation and needs. Please read the Disclosures and Disclaimers set out above. By receiving or reading this report, you agree to be bound by the terms and limitations set out above. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.